Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZEGALOGUE vs CETROTIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for assisted reproductive technology (ART)
Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.
0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.
Terminal elimination half-life is 5-7 hours in healthy adults; in hepatic impairment, half-life may be prolonged up to 12 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 36 hours after subcutaneous administration. This long half-life supports once-daily dosing for continuous Gn RH antagonist effect.
Dasiglucagon is metabolized via proteolytic degradation into smaller peptides and amino acids; CYP enzymes are not involved.
Cetrorelix is metabolized via peptidase cleavage and is primarily eliminated unchanged in urine and feces.
Primarily renal excretion of unchanged drug (approximately 70-80%) and minor hepatic metabolism with biliary/fecal elimination (10-15%).
Primarily renal excretion of unchanged drug (approx. 40-50%) and metabolites; remainder excreted in feces via biliary elimination. Total recovery in urine and feces accounts for >90% of dose.
Approximately 85% bound to albumin and alpha-1-acid glycoprotein.
Approximately 80% bound to plasma proteins, primarily albumin.
0.6-0.8 L/kg, indicating moderate tissue distribution with concentrations in tissues approximately 1.5 times plasma.
Approximately 0.7 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: 40-50% (due to first-pass metabolism); Intramuscular: 90-100%.
Subcutaneous administration: approximately 85% absolute bioavailability compared to intravenous injection.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Not recommended for use in patients with end-stage renal disease (e GFR <15 m L/min/1.73 m2) due to lack of data.
No specific dose adjustment is recommended for patients with renal impairment; however, caution is advised in severe impairment due to limited data.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended in these patients.
No specific dose adjustment is recommended for patients with hepatic impairment; however, caution is advised in severe impairment due to limited data.
Not indicated for pediatric patients; safety and efficacy in patients <18 years have not been established.
Not indicated for pediatric use; safety and efficacy have not been established.
No specific dose adjustment required based on age alone. However, dosing should be cautious due to potential for decreased renal function or comorbidities; monitor renal function and volume status.
Not indicated for geriatric use; safety and efficacy have not been established in women over 65 years.
None.
None.
Risk of serious hypersensitivity reactions including anaphylaxis,May cause nausea and vomiting,Risk of hypoglycemia if used in patients with insulinoma or glucagonoma,May increase blood pressure and heart rate
Hypersensitivity reactions (e.g., anaphylaxis) have been reported.,Ovarian hyperstimulation syndrome (OHSS) may occur; monitor during stimulation.,Use caution in patients with active allergic conditions or history of asthma.
Pheochromocytoma,Insulinoma,Known hypersensitivity to dasiglucagon or any excipients
Hypersensitivity to cetrorelix, Gn RH, or any other Gn RH analog.,Known or suspected pregnancy.,Breastfeeding.,Severe renal impairment (creatinine clearance <30 m L/min).,Pre-existing moderate to severe hepatic impairment.
No specific food interactions. After recovery, administer oral carbohydrates to replenish liver glycogen and prevent recurrent hypoglycemia. Avoid alcohol as it may impair glucose recovery.
No known food interactions. No dietary restrictions required.
Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk cannot be excluded; use only if benefit outweighs risk. Fetal risks: potential for maternal hypoglycemia-induced fetal distress if not treated.
Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than human exposure. No adequate human studies exist.
No data on presence in human milk; dasiglucagon is a peptide likely degraded in GI tract. M/P ratio not determined. Caution in breastfeeding; consider risk of infant exposure vs benefit of treating maternal hypoglycemia.
No data on cetrorelix excretion in human milk. M/P ratio unknown. Given its peptide nature and short half-life, excretion is unlikely but not confirmed. Caution advised; avoid use in nursing mothers unless clearly needed.
No pharmacokinetic data in pregnancy; dosing adjustments not recommended. Use standard dose (0.6 mg) for severe hypoglycemia regardless of trimester.
Cetrorelix is contraindicated in pregnancy; no dosing adjustments apply. Dose modifications are not recommended as drug should not be used.
ZEGALOGUE (dasiglucagon) is a soluble glucagon analog indicated for severe hypoglycemia. It is stable in liquid form, avoiding reconstitution. Onset of action is 10-15 minutes, with blood glucose rise similar to native glucagon. Note that it can cause nausea and vomiting; if patient is unconscious, place in recovery position. Do not use if patient has pheochromocytoma, insulinoma, or known hypersensitivity. Store at room temperature.
Cetrotide (cetrorelix) is a Gn RH antagonist used in controlled ovarian stimulation to prevent premature LH surges. Administer subcutaneously in the lower abdominal wall; rotate sites. Monitor for ovarian hyperstimulation syndrome (OHSS). Onset of action is immediate; does not cause flare effect like Gn RH agonists. Dose adjustment not required in renal or hepatic impairment. Use with caution in patients with allergies to Gn RH analogs or mannitol.
Use only for severe hypoglycemia when patient is unable to take carbs orally or is unconscious.,Inject into buttock, thigh, or abdomen; no need to mix or reconstitute.,After injection, call emergency services immediately.,Administer supplemental carbs (if conscious and can swallow) after blood glucose responds.,Common side effects: nausea, vomiting, headache, injection site pain.,Store at controlled room temperature (20-25°C); do not freeze.
Inject exactly as prescribed, at the same time each day during the stimulation cycle.,Do not skip doses; missing a dose may increase risk of premature ovulation.,Report any signs of allergic reaction, such as rash, hives, or difficulty breathing.,Mild injection site reactions (redness, swelling, itching) are common and usually resolve.,Avoid pregnancy prior to the procedure; use non-hormonal contraception if needed.,Understand the risk of OHSS: symptoms include severe pelvic pain, nausea, vomiting, sudden weight gain, and decreased urination.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZEGALOGUE vs CETROTIDE, answered by our medical review team.
ZEGALOGUE is a GnRH Antagonist that works by ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.. CETROTIDE is a GnRH antagonist that works by Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZEGALOGUE and CETROTIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZEGALOGUE is: Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.. The standard adult dose of CETROTIDE is: 0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZEGALOGUE and CETROTIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZEGALOGUE is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk c. CETROTIDE is classified as Category C. Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.